Navigation Links
Global Lung Cancer Therapeutics Market 2012-2016
Date:2/12/2013

NEW YORK, Feb. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Lung Cancer Therapeutics Market 2012-2016

http://www.reportlinker.com/p01095396/Global-Lung-Cancer-Therapeutics-Market-2012-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of MandAs. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market.

TechNavio's report, the Global Lung Cancer Therapeutics Market 2012-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG.

The other vendors mentioned in the report are

Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYtech Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Table of Contents 01. Executive Summary

02. Introduction

03. Market Coverage

Market Overview

Key Products

04. Market Landscape

Market Size

Market Forecast

04.1 Five Forces Analysis

05. Geographical Segmentation

06. Key Leading Countries

US

Germany

Japan

07. Rate of Incidence and Prevalence

08. Vendor Landscape

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Key Vendor Analysis

15.1 Hoffmann-La Roche Ltd.

Business Overview

Key Information

SWOT Analysis

15.2 Eli Lilly and Co.

Business Overview

Key Information

SWOT Analysis

15.3 Sanofi S.A.

Business Overview

Key Information

SWOT Analysis

15.4 Bristol-Myers Squibb Co.

Business Overview

Key Information

SWOT Analysis

15.5 AstraZeneca plc

Business Overview

Key Information

SWOT Analysis

15.6 Novartis AG

Business Overview

Key Information

SWOT Analysis

15.7 GlaxoSmithKline plc

Business Overview

Key Information

SWOT Analysis

16. Other Reports in this Series

List of Exhibits: Exhibit 1: Global Lung Cancer Therapeutics Market 2012-2016 (US$ billion)

Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012

Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012

Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012

Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.

Exhibit 6: Business Segmentation of Eli Lilly and Co.

Exhibit 7: Business Segmentation of Sanofi S.A.

Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.

Exhibit 9: Business Segmentation of AstraZeneca plc

Exhibit 10: Business Segmentation of Novartis AG

Exhibit 11: Business Segmentation of GlaxoSmithKline plc

To order this report:Therapy Industry: Global Lung Cancer Therapeutics Market 2012-2016

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
2. Natalie Douglas, CEO of Idis, Joins Global Genes
3. RARE Project Board of Directors
4. Natalie Douglas, CEO von Idis, tritt Vorstand von Global Genes
5. RARE Project bei
6. Covance To Present At The Leerink Swann Global Healthcare Conference
7. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
8. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
9. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
10. Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
11. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance ... greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to ... and deadly chromosome abnormality. , After struggling since birth with several health challenges, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
Breaking Medicine News(10 mins):